Thursday, 21 Sep 2017

You are here

Withdrawal of TNF Inibitors Fails in Most RA Patients

The 12 month POET study analyzed 817 rheumatoid arthritis (RA) patients who achieved remission or low disease activity (LDAS) for ≥6 months and then randomized 2:1 to stopping or continuing their TNF inhibitor. They found that stopping TNFi had significantly negative consequences in the negative short-term, with fewer long-term negative consequences to drug cessation.

At the discretion of the rheumatologist, TNFi therapy was restarted within 12 months in 47.5% of those who stopped their TNFi. Worsening was significantly evident looking at patient-reported outcomes (PROs) at 3 months.

Stopping TNFi had a significant negative short-term impact on a broad range of PROs. Long-term negative consequences appeared to be limited and outcomes in patients needing to restart TNFi within the first 6 months tended to be restored at 12 months. 

This trial showed that stopping TNFi treatment in patients with established RA in remission or LDAS resulted in substantially more clinical flares, but that most patients who restarted TNFi treatment quickly regained remission or low disease activity.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.  

Uveitis Events Reduced with Select TNF Inhibitors

Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.

No Increase in Malformations with Etanercept Use During Pregnancy

While there are several reports detailing uncontrolled, observational results of biologic use during pregnancy, most are hampered by low numbers, incomplete data and too small a sample to make reliable judgements regarding the teratogenicity.  A company sponsored claims data analysis has shown that etanercept exposure during pregnancy was not associated with an increase in major congenital malformations (MCMs).